Logo image of NBTX

NANOBIOTIX SA - ADR (NBTX) Stock Price, Quote, News and Overview

NASDAQ:NBTX - Nasdaq - US63009J1079 - ADR - Currency: USD

4.71  +0.12 (+2.61%)

NBTX Quote, Performance and Key Statistics

NANOBIOTIX SA - ADR

NASDAQ:NBTX (6/6/2025, 8:12:49 PM)

4.71

+0.12 (+2.61%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6
52 Week Low2.76
Market Cap223.28M
Shares47.40M
Float39.99M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)09-16 2025-09-16
IPO10-29 2012-10-29


NBTX short term performance overview.The bars show the price performance of NBTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

NBTX long term performance overview.The bars show the price performance of NBTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20

The current stock price of NBTX is 4.71 USD. In the past month the price increased by 42.73%. In the past year, price decreased by -17.37%.

NANOBIOTIX SA - ADR / NBTX Daily stock chart

NBTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.48 335.32B
AMGN AMGEN INC 13.99 156.11B
GILD GILEAD SCIENCES INC 14.53 139.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.69B
REGN REGENERON PHARMACEUTICALS 11.13 53.25B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.23B
ARGX ARGENX SE - ADR 101.9 35.78B
ONC BEONE MEDICINES LTD-ADR 6.55 27.68B
BNTX BIONTECH SE-ADR N/A 26.08B
NTRA NATERA INC N/A 22.36B
BIIB BIOGEN INC 8.42 19.51B
SMMT SUMMIT THERAPEUTICS INC N/A 15.29B

About NBTX

Company Profile

NBTX logo image Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 108 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Company Info

NANOBIOTIX SA - ADR

60 rue de Wattignies

Paris ILE-DE-FRANCE 75012 FR

CEO: Dr. Laurent Levy

Employees: 108

NBTX Company Website

NBTX Investor Relations

Phone: 33140260470

NANOBIOTIX SA - ADR / NBTX FAQ

What is the stock price of NANOBIOTIX SA - ADR today?

The current stock price of NBTX is 4.71 USD. The price increased by 2.61% in the last trading session.


What is the ticker symbol for NANOBIOTIX SA - ADR stock?

The exchange symbol of NANOBIOTIX SA - ADR is NBTX and it is listed on the Nasdaq exchange.


On which exchange is NBTX stock listed?

NBTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NANOBIOTIX SA - ADR stock?

12 analysts have analysed NBTX and the average price target is 12.74 USD. This implies a price increase of 170.56% is expected in the next year compared to the current price of 4.71. Check the NANOBIOTIX SA - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NANOBIOTIX SA - ADR worth?

NANOBIOTIX SA - ADR (NBTX) has a market capitalization of 223.28M USD. This makes NBTX a Micro Cap stock.


How many employees does NANOBIOTIX SA - ADR have?

NANOBIOTIX SA - ADR (NBTX) currently has 108 employees.


What are the support and resistance levels for NANOBIOTIX SA - ADR (NBTX) stock?

NANOBIOTIX SA - ADR (NBTX) has a support level at 3.95. Check the full technical report for a detailed analysis of NBTX support and resistance levels.


Is NANOBIOTIX SA - ADR (NBTX) expected to grow?

The Revenue of NANOBIOTIX SA - ADR (NBTX) is expected to decline by -3.32% in the next year. Check the estimates tab for more information on the NBTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NANOBIOTIX SA - ADR (NBTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NANOBIOTIX SA - ADR (NBTX) stock pay dividends?

NBTX does not pay a dividend.


When does NANOBIOTIX SA - ADR (NBTX) report earnings?

NANOBIOTIX SA - ADR (NBTX) will report earnings on 2025-09-16.


What is the Price/Earnings (PE) ratio of NANOBIOTIX SA - ADR (NBTX)?

NANOBIOTIX SA - ADR (NBTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.64).


What is the Short Interest ratio of NANOBIOTIX SA - ADR (NBTX) stock?

The outstanding short interest for NANOBIOTIX SA - ADR (NBTX) is 0.16% of its float. Check the ownership tab for more information on the NBTX short interest.


NBTX Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to NBTX. When comparing the yearly performance of all stocks, NBTX is one of the better performing stocks in the market, outperforming 77.07% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NBTX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to NBTX. NBTX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NBTX Financial Highlights

Over the last trailing twelve months NBTX reported a non-GAAP Earnings per Share(EPS) of -1.64. The EPS decreased by -33.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -101.06%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-250%
Sales Q2Q%-154%
EPS 1Y (TTM)-33.33%
Revenue 1Y (TTM)-138.62%

NBTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to NBTX. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 33.28% and a revenue growth -3.32% for NBTX


Ownership
Inst Owners24.66%
Ins Owners0.3%
Short Float %0.16%
Short Ratio5.67
Analysts
Analysts86.67
Price Target12.74 (170.49%)
EPS Next Y33.28%
Revenue Next Year-3.32%